Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

90Yttrium Ibritumomab Tiuxetan (Zevalin) Combined with BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Follicular Lymphoma. GELA Phase II Study.

Christian Gisselbrecht, MD, Didier Decaudin, MD, Nicolas Mounier, MD, PhD, Herve Tilly, MD, Vincent Ribrag, MD, Catherine Sebban, MD, Noel Milpied, MD, Franck Morschhauser, MD, Bertrand Coiffier, MD, Steven Le Gouill, MD, PhD, Pierre Lederlin, MD, Richard Delarue, MD, Guy Laurent, MD, Andre Bosly, MD

Blood (2007) 110 (11): 22.

https://doi.org/10.1182/blood.V110.11.22.22

Published: 2007

Journal Articles

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

Karim Belhadj, MD, Olivier Fitoussi, MD, Corinne Haioun, MD, Nicolas Mounier, MD, Pierre Lederlin, MD, Bertrand Coiffier, MD, Christian Recher, MD, Olivier Casasnovas, MD, Catherine Sebban, MD, Christophe Fermé, MD, Herve Tilly, MD, Christian Gisselbrecht, MD

Blood (2006) 108 (11): 3049.

https://doi.org/10.1182/blood.V108.11.3049.3049

Published: 2006

Journal Articles

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Blood (2006) 108 (11): 486.

https://doi.org/10.1182/blood.V108.11.486.486

Published: 2006

Journal Articles

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Blood (2004) 104 (11): 585.

https://doi.org/10.1182/blood.V104.11.585.585

Published: 2004

Journal Articles

Autologous Stem Cell Transplantation (ASCT) as Consolidation Therapy for Patients with Low-Intermediate (LI) Risk Diffuse Large B-Cell Lymphoma (DLBCL) and Overexpression of Bcl2 Protein. Results of the First Interim Analysis of the GELA Trial LNH98-B2.

Pierre Morel, Nicolas Mounier, Josette Briere, Christophe Ferme, Bertrand Coiffier, Herve Tilly, Philippe Gaulard, Pierre Lederlin, Felix Reyes, Christian Gisselbrecht

Blood (2004) 104 (11): 2928.

https://doi.org/10.1182/blood.V104.11.2928.2928

Published: 2004

Journal Articles

Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Karim Belhadj, Félix Reyes, Jean-Pierre Farcet, Hervé Tilly, Christian Bastard, Régis Angonin, Eric Deconinck, Frédéric Charlotte, Véronique Leblond, Eric Labouyrie, Pierre Lederlin, Jean-François Emile, Béatrice Delmas-Marsalet, Bertrand Arnulf, Elie-Serge Zafrani, Philippe Gaulard

Blood (2003) 102 (13): 4261–4269.

https://doi.org/10.1182/blood-2003-05-1675

Published: 2003

Journal Articles

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

Nicolas Mounier, Josette Briere, Christian Gisselbrecht, Jean-Francois Emile, Pierre Lederlin, Catherine Sebban, Francoise Berger, Andre Bosly, Pierre Morel, Herve Tilly, Reda Bouabdallah, Felix Reyes, Philippe Gaulard, Bertrand Coiffier

Blood (2003) 101 (11): 4279–4284.

https://doi.org/10.1182/blood-2002-11-3442

Published: 2003

Journal Articles

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Blood (2001) 97 (1): 101–106.

https://doi.org/10.1182/blood.V97.1.101

Published: 2001

Journal Articles

Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'études des Lymphomes de l'Adulte H89 trial

Christophe Fermé, Catherine Sebban, Christophe Hennequin, Marine Diviné, Pierre Lederlin, Jean Gabarre, Augustin Ferrant, Denis Caillot, Dominique Bordessoule, Pauline Brice, Isabelle Moullet, Françoise Berger, Eric Lepage

Blood (2000) 95 (7): 2246–2252.

https://doi.org/10.1182/blood.V95.7.2246

Published: 2000

Journal Articles

Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome

Hervé Tilly, Philippe Gaulard, Eric Lepage, Charles Dumontet, Jacques Diebold, Isabelle Plantier, Françoise Berger, Michel Symann, Tony Petrella, Pierre Lederlin, Josette Brière

Blood (1997) 90 (9): 3727–3734.

https://doi.org/10.1182/blood.V90.9.3727

Published: 1997

NARROW

90Yttrium Ibritumomab Tiuxetan (Zevalin) Combined with BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Follicular Lymphoma. GELA Phase II Study.

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Autologous Stem Cell Transplantation (ASCT) as Consolidation Therapy for Patients with Low-Intermediate (LI) Risk Diffuse Large B-Cell Lymphoma (DLBCL) and Overexpression of Bcl2 Protein. Results of the First Interim Analysis of the GELA Trial LNH98-B2.

Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'études des Lymphomes de l'Adulte H89 trial

Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only